{"entity":{"id":"nct07040436","kind":"trial","name":"Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1","aka":[],"tldr":"A phase 1/2 trial of OPM-101 run by Oncodesign Precision Medicine, not yet recruiting.","summary":"Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1 is a phase 1/2 interventional study registered as NCT07040436 by Oncodesign Precision Medicine, with 41 participants planned, started 2025-09. Conditions recorded: Advanced Melanoma. Interventions recorded: OPM-101.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07040436","url":"https://clinicaltrials.gov/study/NCT07040436"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["opm-101"],"companies":["oncodesign-precision-medicine"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07040436","phase":"1/2","setting":"REVERT Study: A Phase 1b/2a Study to Assess the Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1","sponsor":"Oncodesign Precision Medicine","enrolled":41,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07040436/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"opm-101","kind":"drug","name":"OPM-101","route":"/drugs/opm-101/"}],"company":[{"id":"oncodesign-precision-medicine","kind":"company","name":"Oncodesign Precision Medicine","route":"/companies/oncodesign-precision-medicine/"}]}}